Senate committee takes Pfizer, Mylan and others to task over naloxone price increases


The Senate Special Committee on Aging isn’t stopping with its push to hold drugmakers accountable for their hefty price increases. Now, it wants 5 pharmas to explain the rising cost of naloxone, a med that’s used to reverse the effects of opioids.

U.S. senators Susan Collins (R-ME) and Claire McCaskill (D-MO)--the committee’s chairwoman and ranking member--have reached out to Pfizer ($PFE), Mylan ($MYL), Amphastar ($AMPH), Adapt Pharma and Kaleo, asking them to account for their pricing moves on the med, the cost of which has been heading north alongside opioid abuse and overdose rates.

“As we work to address a complex public health crisis, it is important that naloxone, a potentially lifesaving tool, be accessible,” they wrote.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Drugmakers have benefitted from the surge of opioid-related deaths in the U.S.; last year, Bloomberg reported that the drug’s price had risen tenfold in recent years, with state and local governments shelling out to make the med more widely available.

And it isn’t the first time lawmakers have taken note. Amphastar, in particular, came under fire last year for jacking up the price of its injectable version to $41 per dose in January 2015 from $19 per dose in June 2014. Price hikes like those are getting in the way of distribution of the med, vocal pricing critics Sen. Bernie Sanders (I-VT) and Rep. Elijah Cummings (D-MD) have said.

Amphastar, for its part, told Bloomberg recently that it offers 9 states rebates on its moneymaker, while rival Adapt says it hasn’t raised prices since its nasal-spray version, Narcan, won FDA approval late last year. Politico has reported that Kaleo, on the other hand, in two years raised prices on its autoinjecting version to $3,750 per two-dose package from $575.

The Senate Special Committee on Aging has had quite a few questions for price-hiking pharmas over the last year; in April, the committee grilled Valeant's then-CEO J. Michael Pearson for at least 9 hours in advance of a public hearing on price increases.

- read the release 
- get more from Bloomberg

Special Report: 10 big brands keep pumping out big bucks, with a little help from price hikes

Related Articles:
Senate committee grills Valeant CEO Pearson for 9 hours: Bloomberg
Adapt's new bargain-priced OD antidote enters contentious market
Already riding naloxone boom, Amphastar plots nasal spray to rival old formulas
Sen. Sanders joins Maryland rep for game of pricing hardball with Amphastar
Maryland Rep joins chorus of Amphastar critics, urging OD drug price deal
Vermont governor demands price cut for Amphastar's overdose antidote
Amphastar pays some rebates after price of overdose drug doubles

Suggested Articles

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

Companies routinely update analysts, but a new SEC order for tiny TherapeuticsMD offers a lesson—or reminder—about when to keep quiet.

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…